Rakovina Therapeutics’ management will deliver a brief corporate overview and then be available for questions and discussions...
Publication to be available on pre-print server, bioRxiv, and will be submitted for scientific journal peer-review
Pre-clinical studies show potential synergy in treatment of solid tumors by combining a PARP inhibitor with inhibition of HDAC enzymes.
The lead optimization program being conducted in collaboration with the University of British Columbia is progressing as planned...
The data presented suggested promising activity for bi-functional kt-4000 series compounds...
Rakovina’s presentation will highlight the development of its drug candidates as a potential treatment of sarcomas and soft tissue tumors..